[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Ambu Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":120},{"warningLetters":4,"total":119},[5,33,57,78,101],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1927,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-16T04:00:00Z\">08\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fking-systems-corp-dba-ambu-inc-661617-08162023\">King Systems Corp. dba Ambu, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambu-usa-661617-06042025\">\u003Ctime datetime=\"2025-06-16T04:00:00Z\">06\u002F16\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Block\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>King Systems Corp. dba Ambu, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6721 Columbia Gateway Drive, Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Columbia\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21046\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 661617\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 16, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Block:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, King Systems Corp., dba Ambu, Inc., located at 15011 Herriman Blvd, Noblesville, IN 46060 on two days from May 15, 2023 through May 16, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your\u003Cbr>\nfirm is a manufacturer of the King LTS-D branded supraglottic airway with gastric access lumen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the King LTS-D branded supraglottic airway with gastric access lumen is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Statements on your website (https:\u002F\u002Fwww.ambuusa.com\u002Fairway-management-andanaesthesia\u002Flaryngeal-tubes\u002Fproduct\u002Fambu-king-lts-d-disposable-laryngeal-tube) promote the device with an intended use for pediatric populations weighing less than 5 kg, 5-12kg, 12-25kg, and 25-35 kg. However, the cleared indication for use for your device is for adult patients (K033189.pdf (fda.gov); K033186.pdf (fda.gov); K021634.pdf (fda.gov), and not for pediatric sizes. Use of this device in a pediatric population raise different questions of safety and effectiveness that may lead to patient adverse events. Therefore, please remove these unsupported performance claims from your website, or please provide a 510(k) with this proposed indication for use. For additional information, please refer to the following guidance: Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 661617\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Malvina Eydelman\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT &amp; Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations, Division 1 - East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteven Block\n\nRecipient Title\n\nPresident & CEO\n\nKing Systems Corp. dba Ambu, Inc.\n\n6721 Columbia Gateway Drive, Suite 200\n\nColumbia, MD 21046\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 661617\n\nAugust 16, 2023\n\nDear Mr. Block:\n\nDuring an inspection of your firm, King Systems Corp., dba Ambu, Inc., located at 15011 Herriman Blvd, Noblesville, IN 46060 on two days from May 15, 2023 through May 16, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your\n\nfirm is a manufacturer of the King LTS-D branded supraglottic airway with gastric access lumen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection also revealed that the King LTS-D branded supraglottic airway with gastric access lumen is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nThe device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nStatements on your website (https:\u002F\u002Fwww.ambuusa.com\u002Fairway-management-andanaesthesia\u002Flaryngeal-tubes\u002Fproduct\u002Fambu-king-lts-d-disposable-laryngeal-tube) promote the device with an intended use for pediatric populations weighing less than 5 kg, 5-12kg, 12-25kg, and 25-35 kg. However, the cleared indication for use for your device is for adult patients (K033189.pdf (fda.gov); K033186.pdf (fda.gov); K021634.pdf (fda.gov), and not for pediatric sizes. Use of this device in a pediatric population raise different questions of safety and effectiveness that may lead to patient adverse events. Therefore, please remove these unsupported performance claims from your website, or please provide a 510(k) with this proposed indication for use. For additional information, please refer to the following guidance: Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov).\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 661617 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Malvina Eydelman\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT & Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations, Division 1 - East","King Systems Corp. dba Ambu, Inc.","king-systems-corp-dba-ambu-inc-661617-08162023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fking-systems-corp-dba-ambu-inc-661617-08162023","2026-10-26T08:09:09.153468+00:00","Warning Letter","Closed Out","2023-08-22","661617","Medical Devices","2025-06-16","Steven Block","2026-08-20T00:46:11.037+00:00","VIA UNITED PARCEL SERVICE","2023-08-16",{"id":34,"raw":35,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":39,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":20,"action_taken_date":56,"medical_device_id":20,"response_letter_date":20},16,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-10T04:00:00Z\">04\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffareva-amboise-723502-04102026\">Fareva Amboise\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David L. Rapy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fareva Amboise\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Zone Industrielle 29, route des industries\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>37530\u003C\u002Fspan> \u003Cspan>Pocé-sur-Cisse\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>France\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 10, 2026\u003C\u002Fp>\u003Cp>CMS Case: 723502\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Rapy:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fareva Amboise, FEI 3000234005, at Zone Industrielle 29, route des Industries 37 530 Pocé-sur-Cisse, France from September 8 to 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 7, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences dated December 11, 2025, December 23, 2025, and February 6, 2026.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Airflow visualization studies performed for your Grade A \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic filling line, which is used to fill animal drug products for the U.S. market, did not demonstrate unidirectional air flow and revealed multiple deficiencies in airflow patterns and aseptic practices. For example:\u003C\u002Fp>\u003Cul>\u003Cli>During \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation, air flowed from the operator (positioned in the Grade B area while leaning into the barrier) toward the \u003Cstrong>(b)(4)\u003C\u002Fstrong> intervention site where uncovered \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were exposed.\u003Cbr>• Air flowed upward towards the Grade B area when \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, leading to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and on top of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rather than maintaining unidirectional flow away from critical surfaces.\u003Cbr>• Laminar flow patterns during interventions performed around the filling area showed a tendency to stagnate and flow upward in the area between \u003Cstrong>(b)(4)\u003C\u002Fstrong> where operators make tubing connections.\u003Cbr>• Airflow was turbulent with an \u003Cstrong>(b)(4)\u003C\u002Fstrong> flow while stoppers were transferred from the stopper bowl to the stoppering machine and over the conveyor moving open bottle.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, your firm has not conducted dynamic airflow studies during filling and stoppering operations. The airflow studies reviewed during the inspection do not include airflow patterns during filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers \u003Cstrong>(b)(4)\u003C\u002Fstrong> filled on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> production line, demonstrating incomplete qualification of your aseptic processing conditions.\u003C\u002Fp>\u003Cp>Your response acknowledges inadequacies in the airflow studies reviewed during the inspection and references previous smoke studies (not provided during inspection) that purportedly confirm adequate airflow. However, you committed to conduct new dynamic smoke studies on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic filling line under external consultant supervision and provided an \"Evaluation of Smoke Studies\" (December 8-19, 2025) in one of your response updates. The evaluation recognizes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> has outdated equipment and environmental design causing non-conformities, including non-laminar flow issues that cannot be corrected through practice improvements alone, and proposes line improvements and procedural changes to mitigate the identified risks.\u003C\u002Fp>\u003Cp>Your response is inadequate. While your December 2025 smoke studies evaluation identifies critical non-conformities requiring correction, you provide no specific timelines or deadlines for implementing the recommended corrections. The reference to change control AMB-CC-2025-227 is insufficient without committed completion dates. Also of note, the document you identified as the \"Risk assessment on smoke studies\" does not appear to correspond to the document referenced in your response attachments. Without a risk assessment, there is no information regarding the impact of the identified deficiencies on sterile drug products manufactured in your aseptic processing areas.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Technique and Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Poor aseptic practices occurred during set up and filling operations of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> including the following:\u003C\u002Fp>\u003Cul>\u003Cli>Inadequate handling of materials, sterile components and equipment:\u003Cbr>o An operator removed empty bottles from the Grade A area by hand into the Grade B area. Additionally, the operator later returned the bottles to the critical area for filling without disinfecting them.\u003Cbr>o An operator introduced a \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> into the Grade A area without disinfection, then repeatedly reached over the unprotected sterile parts (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to make tubing connections.\u003Cbr>o An operator removed protective \u003Cstrong>(b)(4)\u003C\u002Fstrong> from sanitized equipment parts in the Grade B area, then transferred it into Grade A for installation.\u003C\u002Fli>\u003Cli>Inadequate personnel practices\u003Cbr>o Failure to consistently use slow and controlled movements during aseptic operations and while performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> connections.\u003Cbr>o Reaching over sterilized equipment and positioning of arms directly above sterile contact surfaces.\u003Cbr>o Reaching into and over sterile components and equipment, creating direct contamination potential for sterile product contact surfaces.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response you committed to conducting a re-assessment of all aseptic practices. You proposed the implementation of specific actions to reduce risk during interventions to the Grade A area and periodic self-inspections by the production and QA managers. Additionally, you provided evidence of personnel re-training on aseptic behavior.\u003C\u002Fp>\u003Cp>Your response is inadequate because it did not investigate the impact of these poor aseptic practices on the sterile drugs you manufactured. Further, the response does not provide sufficient details regarding the frequency and scope of the proposed self- inspections to be implemented to address the lack of oversight of aseptic behavior of the operators.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Simulation (Media Fills)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills do not adequately simulate commercial operations. For example, FDA investigators observed significantly more \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions during aseptic filling operations on September 8, 2025, and in their review of the aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> than those that were documented in the corresponding media fill records, which indicates your media fills do not simulate worst-case conditions.\u003C\u002Fp>\u003Cp>Additionally, complete information regarding the type, frequency, and timing of interventions was not consistently documented in the media fill or batch production records. For example, you performed numerous interventions during the filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> which you did not document in the batch record.\u003C\u002Fp>\u003Cp>Furthermore, you do not have written procedures for vial rejection (e.g., rejecting vials during interventions or after \u003Cstrong>(b)(4)\u003C\u002Fstrong>.) You reject vials after \u003Cstrong>(b)(4)\u003C\u002Fstrong> during media fills, but your lack of written procedures means there is no basis to conclude this is representative of routine production. You also fail to keep records of such rejections during commercial batches, which prevents any meaningful comparison with your media fill.\u003C\u002Fp>\u003Cp>In response to this deficiency, you committed to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for interventions, add reminders for complete intervention documentation in batch records, analyze data to develop new media fill protocols, implement intervention batch documentation forms verified against video recordings, and establish new SOPs with operator training for vial removal activities.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the potential impact of the observed deficiencies or propose interim measures to mitigate risk to product quality. Furthermore, your response does not address overall aseptic processing deficiencies, including but not limited to inadequate airflow studies, personnel behavior issues, and inadequate process simulations. When a media fill program fails to adequately account for contamination risk factors or accurately replicate actual drug product exposure conditions, it becomes difficult to properly evaluate the state of process control or provide adequate sterility assurance.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Monitoring of Personnel In Aseptic Areas\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to ensure adequate monitoring of personnel operating within the critical area. For example, personnel whose hands and forearms extend into the Grade A area — where open vials, exposed sterile stoppers, and sterile equipment surfaces are present — were held to Grade B requirements (\u003Cstrong>(b)(4)\u003C\u002Fstrong> alert, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU action limits) when their hands were monitored upon exit. For example, on April 17, 2025, during aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>(US batch), \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU’s of \u003Cem>Corynebacterium tuberculostearicum\u003C\u002Fem>, were recovered on the right forearm of Personnel ID:\u003Cstrong>(b)(6)\u003C\u002Fstrong>, who participated in the filling activities.\u003C\u002Fp>\u003Cp>You initiated a deviation to review \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and concluded that aseptic practices and environmental controls were compliant, despite the recovery of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs on an operator's forearm who had direct contact with the Grade A environment. You committed to implementing the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to prevent \u003Cstrong>(b)(4)\u003C\u002Fstrong> under laminar flow, controlling \u003Cstrong>(b)(4)\u003C\u002Fstrong> and forearms to Grade A specifications, and improving the stopper bowl design to reduce interventions.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to acknowledge that personnel monitoring requirements should be based on actual Grade A exposure and contamination risk rather than arbitrary area designations. You concluded that your practices were \"compliant\" despite clear evidence that an operator with \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs on their forearm had direct contact with the Grade A environment during aseptic operations. You failed to provide an investigation into the contamination source or potential product impact to determine if batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> or other batches processed by contaminated personnel pose sterility risks to distributed products. Additionally, you failed to provide documentation evidencing implementation of the proposed corrections such as revised personnel monitoring procedures and to establish interim controls or enhanced supervision.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr> All human interactions within the ISO 5 area\u003Cbr> Equipment placement and ergonomics\u003Cbr> Air quality in the ISO 5 area and surrounding room\u003Cbr> Facility layout\u003Cbr> Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Smoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\u003C\u002Fli>\u003Cli>A comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate control systems to prevent contamination during aseptic processing 211.42(c)(10)(v)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate systems for cleaning and disinfection\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your aseptic processing operation is inadequately designed to prevent contamination of sterile drug products. For example, the stopper bowl equipment, which directly contacts \u003Cstrong>(b)(4)\u003C\u002Fstrong> container closure components, has parts that are permanently fixed to the machine and cannot be disassembled. This design prevents adequate cleaning and sterilization of critical contact surfaces.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our investigators observed that equipment \u003Cstrong>(b)(4)\u003C\u002Fstrong> were disinfected and stored in a Grade C area, then transported through a Grade B area and installed in the Grade A area without re-disinfection. Additionally, your firm failed to maintain records of when equipment disinfection occurred\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and you lack cleaning validation data to support time limits for holding disinfected equipment prior to installation in the Grade A area.\u003C\u002Fp>\u003Cp>Your facility does not routinely use a sporicidal agent on equipment surfaces within the Grade A filling barrier. Further, your firm has not conducted or provided validated disinfection efficacy studies to demonstrate the effectiveness of disinfection procedures for all surfaces in the Grade A filling area. This includes filling machine \u003Cstrong>(b)(4)\u003C\u002Fstrong> constructed from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Moreover, during our inspection, apparent \u003Cstrong>(b)(4)\u003C\u002Fstrong>, scratch marks and signs of wear were observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the aseptic filling and capping lines. While you had performed the preventive maintenance (PM) on these equipment pieces, the preventive maintenance activities did not identify the damage on the equipment parts and corrective actions were not implemented until the deficiencies were noted during the inspection.\u003C\u002Fp>\u003Cp>You acknowledged a design flaw in your equipment and committed to creating a new stopper bowl part that your operators can sterilize and install, with plans to incorporate this intervention into upcoming smoke studies. You also committed to revising assembly procedures for the stopper bowl, training your operators on these updates, and implementing reinforced decontamination activities that include \u003Cstrong>(b)(4)\u003C\u002Fstrong> sporicidal \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatments followed by surface monitoring to verify effectiveness. To address inadequate transport of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Grade C to Grade A areas, you committed to updating procedures that will require your personnel to sterilize or disinfect \u003Cstrong>(b)(4)\u003C\u002Fstrong> before entering Grade A environments, with particular emphasis on parts that contact products directly, and you committed to validate these disinfection procedures. You proposed implementing \u003Cstrong>(b)(4)\u003C\u002Fstrong> sporicidal decontamination in Grade A areas while revising procedures that define methodology and frequency. Regarding disinfection efficacy studies for all Grade A surface materials, you referenced an ongoing validation that your provider is conducting and will generate comprehensive validation data. Finally, you presented a \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the inspection and committed to assessing all your aseptic process equipment for degradation risks, verifying your preventive maintenance program, and implementing equipment defect verification and correction during \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response to these observations is inadequate. While your response addresses the identified deficiencies, you failed to provide documentation evidencing the implementation of the proposed corrections or interim control measures such as validation protocols, revised procedures, or service provider contracts. You did not conduct an adequate risk assessment to determine if the drug products manufactured by your facility for the U.S. market are compromised for sterility. Additionally, we are concerned that your preventive maintenance program did not identify the improper equipment conditions, including scratches, cracks, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, until these deficiencies were pointed out during our inspection. Your response lacks scientific justification for the proposed \u003Cstrong>(b)(4)\u003C\u002Fstrong> sporicidal treatment frequency and fails to adequately explain why routine sporicidal treatment was not previously considered necessary for aseptic operations. Furthermore, your preventive maintenance response does not provide sufficient scientific rationale for the proposed maintenance intervals and inadequately addresses how your previous maintenance program failed to detect obvious equipment defects that were readily apparent to our investigators. The absence of supporting documentation, combined with the failure to assess potential impact on distributed products and the systemic oversight failures in your maintenance program, demonstrates insufficient corrective action to ensure ongoing compliance with current good manufacturing practice requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records, and you do not maintain a backup file of data. 21 CFR 211.68(b)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your systems do not have the appropriate controls to prevent data deletion and record modifications.\u003C\u002Fp>\u003Cp>For example, your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle counters to perform particle monitoring in classified areas. During the inspection on September 10, 2025, our investigator observed that operators could modify system dates, adjust alarm limits, and access settings without restriction. The equipment displayed that network user authentication was not enforced, and management confirmed that no controls were in place to ensure the integrity of printed data records.\u003C\u002Fp>\u003Cp>Review of electronic data stored on your particle counters revealed multiple instances where Grade A action limits for particle counts were exceeded. However, your firm could not produce original printed documentation of these failing results despite extensive searches of batch records and data storage locations. Initial failing particle count results in Grade A areas were not recorded in batch records. Instead, retests were performed, and only conforming retest results were retained and included in production documentation. There was no evidence in batch records of the original failing results or required corrective actions such as notifying operators or cleaning the area.\u003C\u002Fp>\u003Cp>Additionally, you lack adequate data backup and retention procedures. For example, your firm's vendor performed a calibration activity which deleted all electronic data prior to the calibration. You did not have backups of this data.\u003C\u002Fp>\u003Cp>You acknowledged the data integrity failures with your \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle counters and proposed several corrective actions. You opened a deviation to document the incident and committed to retraining all personnel on data retention obligations. You purchased new \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment with electronic data collection capabilities that will be connected to a server, proposed to conduct a system-wide review of other in-process control equipment for similar upgrades, and to investigate the root cause of particulate contamination at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine laminar airflow. You also committed to developing an investment plan for upgrading older equipment and eliminating reliance on paper-based data collection systems.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the immediate and ongoing data integrity risks during the implementation timeline. Your response lacks sufficient interim controls to prevent data manipulation, provides no enhanced Quality Unit oversight of current \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations, and offers only \"retraining\" as an immediate remedy for what appears to be data suppression. You did not commit to assessing the impact on already-released batches or implementing enhanced supervision during the interim period.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of computer system performance and security. Provide a report that identifies vulnerabilities in design and controls, and a thorough corrective action and preventive action (CAPA) plan for each of your laboratory or production computer systems, which contains the following elements:\u003Cbr>o A list of all hardware (both standalone and networked) and software used.\u003Cbr>o Identification and evaluation of vulnerabilities in performance and security of all of these computer systems, including but not limited to their configurations, administrative rights, password controls, audit trails capabilities and state of implementation for each system, qualification\u002Fvalidation status, deviation history, backup capabilities, network requirements, completeness of data records, suitability of current hardware\u002Fsoftware for its intended use(s), change management, and management oversight.\u003Cbr>o An Assessment of each system to determine if unique usernames and passwords are used.\u003Cbr>o An evaluation of your policies and procedures regarding computers and data governance with special emphasis on audit trails, prohibiting data deletion, and appropriate modifications of results. Specify how your firm prevents data deletion and undocumented\u002Finappropriate modifications of data. Also describe how you ensure original data and information are always preserved. Provide your procedures for audit trail review. Provide requirements for data retention and backup for all laboratory and production systems.\u003C\u002Fli>\u003Cli>A summary of your interim controls to assure reliable performance and security while your CAPA plan is being implemented.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture prescription \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosage form human drug products used to treat various conditions including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your cleaning procedures for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, non-dedicated manufacturing equipment was inadequate. For example,\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> residues were observed on the gasket of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> residues were observed inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During the inspection you collected and analyzed samples of the residue. The active pharmaceutical ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> was detected.\u003C\u002Fp>\u003Cp>In your response, you state that additional testing had been performed and confirmed the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an inactive ingredient which is found in multiple drug products. You then stated that there was no impact on the batches manufactured and distributed, as it was part of the formulation of multiple drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate. The presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from previous batches detected indicates the potential for active ingredients from previous batches to cross contaminate other drug products you manufactured. You failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry. Furthermore, you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from surfaces of your drug product manufacturing equipment.\u003C\u002Fp>\u003Cp>It is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of results from testing retains samples of all drug product batches within expiry manufactured on non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment. You should test all other active ingredients processed in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment. Additionally, provide your scientific rationale for any specification related to cross contamination levels. If testing yields an out-of-specification (OOS) result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload).\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>You must correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of drugs manufactured at Fareva Amboise Zone Industrielle 29, route des industries 37530 Pocé-sur-Cisse - France under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Drugs that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 723502 FEI 3000234005 and ATTN: Dayna I. Martínez when replying.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dillard Woody\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.63 (equipment design).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.182 (equipment cleaning records).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.67 (equipment cleaning and maintenance).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> While this document does not specifically reference the Center for Veterinary Medicine, its contents may be helpful as sterile animal drugs and human drugs produced by aseptic processing are subject to the same CGMP requirements.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. David L. Rapy\n\nRecipient Title\n\nGeneral Manager\n\nFareva Amboise\n\nZone Industrielle 29, route des industries\n\n37530 Pocé-sur-Cisse\n\nFrance\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nApril 10, 2026\nCMS Case: 723502\nWARNING LETTER\nDear Mr. Rapy:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fareva Amboise, FEI 3000234005, at Zone Industrielle 29, route des Industries 37 530 Pocé-sur-Cisse, France from September 8 to 16, 2025.\nThis warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 7, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences dated December 11, 2025, December 23, 2025, and February 6, 2026.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nInadequate Smoke Studies\nAirflow visualization studies performed for your Grade A (b)(4) aseptic filling line, which is used to fill animal drug products for the U.S. market, did not demonstrate unidirectional air flow and revealed multiple deficiencies in airflow patterns and aseptic practices. For example:\nDuring (b)(4) installation, air flowed from the operator (positioned in the Grade B area while leaning into the barrier) toward the (b)(4) intervention site where uncovered (b)(4) on the (b)(4) were exposed.\n• Air flowed upward towards the Grade B area when (b)(4) was (b)(4), leading to the (b)(4) and on top of (b)(4), rather than maintaining unidirectional flow away from critical surfaces.\n• Laminar flow patterns during interventions performed around the filling area showed a tendency to stagnate and flow upward in the area between (b)(4) where operators make tubing connections.\n• Airflow was turbulent with an (b)(4) flow while stoppers were transferred from the stopper bowl to the stoppering machine and over the conveyor moving open bottle.\nFurthermore, your firm has not conducted dynamic airflow studies during filling and stoppering operations. The airflow studies reviewed during the inspection do not include airflow patterns during filling of (b)(4) containers (b)(4) filled on the (b)(4) production line, demonstrating incomplete qualification of your aseptic processing conditions.\nYour response acknowledges inadequacies in the airflow studies reviewed during the inspection and references previous smoke studies (not provided during inspection) that purportedly confirm adequate airflow. However, you committed to conduct new dynamic smoke studies on the (b)(4) aseptic filling line under external consultant supervision and provided an \"Evaluation of Smoke Studies\" (December 8-19, 2025) in one of your response updates. The evaluation recognizes that (b)(4) has outdated equipment and environmental design causing non-conformities, including non-laminar flow issues that cannot be corrected through practice improvements alone, and proposes line improvements and procedural changes to mitigate the identified risks.\nYour response is inadequate. While your December 2025 smoke studies evaluation identifies critical non-conformities requiring correction, you provide no specific timelines or deadlines for implementing the recommended corrections. The reference to change control AMB-CC-2025-227 is insufficient without committed completion dates. Also of note, the document you identified as the \"Risk assessment on smoke studies\" does not appear to correspond to the document referenced in your response attachments. Without a risk assessment, there is no information regarding the impact of the identified deficiencies on sterile drug products manufactured in your aseptic processing areas.\nPoor Aseptic Technique and Cleanroom Behavior\nPoor aseptic practices occurred during set up and filling operations of (b)(4) batches (b)(4) including the following:\nInadequate handling of materials, sterile components and equipment:\no An operator removed empty bottles from the Grade A area by hand into the Grade B area. Additionally, the operator later returned the bottles to the critical area for filling without disinfecting them.\no An operator introduced a (b)(4) bag containing (b)(4) into the Grade A area without disinfection, then repeatedly reached over the unprotected sterile parts ((b)(4)) to make tubing connections.\no An operator removed protective (b)(4) from sanitized equipment parts in the Grade B area, then transferred it into Grade A for installation.\nInadequate personnel practices\no Failure to consistently use slow and controlled movements during aseptic operations and while performing (b)(4) connections.\no Reaching over sterilized equipment and positioning of arms directly above sterile contact surfaces.\no Reaching into and over sterile components and equipment, creating direct contamination potential for sterile product contact surfaces.\nIn your response you committed to conducting a re-assessment of all aseptic practices. You proposed the implementation of specific actions to reduce risk during interventions to the Grade A area and periodic self-inspections by the production and QA managers. Additionally, you provided evidence of personnel re-training on aseptic behavior.\nYour response is inadequate because it did not investigate the impact of these poor aseptic practices on the sterile drugs you manufactured. Further, the response does not provide sufficient details regarding the frequency and scope of the proposed self- inspections to be implemented to address the lack of oversight of aseptic behavior of the operators.\nInadequate Process Simulation (Media Fills)\nYour media fills do not adequately simulate commercial operations. For example, FDA investigators observed significantly more (b)(4) interventions during aseptic filling operations on September 8, 2025, and in their review of the aseptic filling of (b)(4) batch (b)(4) than those that were documented in the corresponding media fill records, which indicates your media fills do not simulate worst-case conditions.\nAdditionally, complete information regarding the type, frequency, and timing of interventions was not consistently documented in the media fill or batch production records. For example, you performed numerous interventions during the filling of (b)(4) batch (b)(4) which you did not document in the batch record.\nFurthermore, you do not have written procedures for vial rejection (e.g., rejecting vials during interventions or after (b)(4).) You reject vials after (b)(4) during media fills, but your lack of written procedures means there is no basis to conclude this is representative of routine production. You also fail to keep records of such rejections during commercial batches, which prevents any meaningful comparison with your media fill.\nIn response to this deficiency, you committed to establishing a (b)(4) process for interventions, add reminders for complete intervention documentation in batch records, analyze data to develop new media fill protocols, implement intervention batch documentation forms verified against video recordings, and establish new SOPs with operator training for vial removal activities.\nYour response is inadequate because it fails to address the potential impact of the observed deficiencies or propose interim measures to mitigate risk to product quality. Furthermore, your response does not address overall aseptic processing deficiencies, including but not limited to inadequate airflow studies, personnel behavior issues, and inadequate process simulations. When a media fill program fails to adequately account for contamination risk factors or accurately replicate actual drug product exposure conditions, it becomes difficult to properly evaluate the state of process control or provide adequate sterility assurance.\nInadequate Monitoring of Personnel In Aseptic Areas\nYour firm failed to ensure adequate monitoring of personnel operating within the critical area. For example, personnel whose hands and forearms extend into the Grade A area — where open vials, exposed sterile stoppers, and sterile equipment surfaces are present — were held to Grade B requirements ((b)(4) alert, (b)(4) CFU action limits) when their hands were monitored upon exit. For example, on April 17, 2025, during aseptic filling of (b)(4), batch (b)(4)(US batch), (b)(4) CFU’s of Corynebacterium tuberculostearicum, were recovered on the right forearm of Personnel ID:(b)(6), who participated in the filling activities.\nYou initiated a deviation to review (b)(4) batch (b)(4) and concluded that aseptic practices and environmental controls were compliant, despite the recovery of (b)(4) CFUs on an operator's forearm who had direct contact with the Grade A environment. You committed to implementing the use of (b)(4) to prevent (b)(4) under laminar flow, controlling (b)(4) and forearms to Grade A specifications, and improving the stopper bowl design to reduce interventions.\nYour response is inadequate because you failed to acknowledge that personnel monitoring requirements should be based on actual Grade A exposure and contamination risk rather than arbitrary area designations. You concluded that your practices were \"compliant\" despite clear evidence that an operator with (b)(4) CFUs on their forearm had direct contact with the Grade A environment during aseptic operations. You failed to provide an investigation into the contamination source or potential product impact to determine if batch (b)(4) or other batches processed by contaminated personnel pose sterility risks to distributed products. Additionally, you failed to provide documentation evidencing implementation of the proposed corrections such as revised personnel monitoring procedures and to establish interim controls or enhanced supervision.\nIn response to this letter, provide the following:\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n All human interactions within the ISO 5 area\n Equipment placement and ergonomics\n Air quality in the ISO 5 area and surrounding room\n Facility layout\n Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nSmoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\nA comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\n2. Your firm failed to establish adequate control systems to prevent contamination during aseptic processing 211.42(c)(10)(v)\nInadequate systems for cleaning and disinfection\nYour aseptic processing operation is inadequately designed to prevent contamination of sterile drug products. For example, the stopper bowl equipment, which directly contacts (b)(4) container closure components, has parts that are permanently fixed to the machine and cannot be disassembled. This design prevents adequate cleaning and sterilization of critical contact surfaces.1\nOur investigators observed that equipment (b)(4) were disinfected and stored in a Grade C area, then transported through a Grade B area and installed in the Grade A area without re-disinfection. Additionally, your firm failed to maintain records of when equipment disinfection occurred2 and you lack cleaning validation data to support time limits for holding disinfected equipment prior to installation in the Grade A area.\nYour facility does not routinely use a sporicidal agent on equipment surfaces within the Grade A filling barrier. Further, your firm has not conducted or provided validated disinfection efficacy studies to demonstrate the effectiveness of disinfection procedures for all surfaces in the Grade A filling area. This includes filling machine (b)(4) constructed from (b)(4).3\nMoreover, during our inspection, apparent (b)(4), scratch marks and signs of wear were observed on the (b)(4) for the aseptic filling and capping lines. While you had performed the preventive maintenance (PM) on these equipment pieces, the preventive maintenance activities did not identify the damage on the equipment parts and corrective actions were not implemented until the deficiencies were noted during the inspection.\nYou acknowledged a design flaw in your equipment and committed to creating a new stopper bowl part that your operators can sterilize and install, with plans to incorporate this intervention into upcoming smoke studies. You also committed to revising assembly procedures for the stopper bowl, training your operators on these updates, and implementing reinforced decontamination activities that include (b)(4) sporicidal (b)(4) treatments followed by surface monitoring to verify effectiveness. To address inadequate transport of (b)(4) from Grade C to Grade A areas, you committed to updating procedures that will require your personnel to sterilize or disinfect (b)(4) before entering Grade A environments, with particular emphasis on parts that contact products directly, and you committed to validate these disinfection procedures. You proposed implementing (b)(4) sporicidal decontamination in Grade A areas while revising procedures that define methodology and frequency. Regarding disinfection efficacy studies for all Grade A surface materials, you referenced an ongoing validation that your provider is conducting and will generate comprehensive validation data. Finally, you presented a (b)(4) during the inspection and committed to assessing all your aseptic process equipment for degradation risks, verifying your preventive maintenance program, and implementing equipment defect verification and correction during (b)(4).\nYour response to these observations is inadequate. While your response addresses the identified deficiencies, you failed to provide documentation evidencing the implementation of the proposed corrections or interim control measures such as validation protocols, revised procedures, or service provider contracts. You did not conduct an adequate risk assessment to determine if the drug products manufactured by your facility for the U.S. market are compromised for sterility. Additionally, we are concerned that your preventive maintenance program did not identify the improper equipment conditions, including scratches, cracks, and (b)(4), until these deficiencies were pointed out during our inspection. Your response lacks scientific justification for the proposed (b)(4) sporicidal treatment frequency and fails to adequately explain why routine sporicidal treatment was not previously considered necessary for aseptic operations. Furthermore, your preventive maintenance response does not provide sufficient scientific rationale for the proposed maintenance intervals and inadequately addresses how your previous maintenance program failed to detect obvious equipment defects that were readily apparent to our investigators. The absence of supporting documentation, combined with the failure to assess potential impact on distributed products and the systemic oversight failures in your maintenance program, demonstrates insufficient corrective action to ensure ongoing compliance with current good manufacturing practice requirements.\nIn response to this letter, provide the following:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records, and you do not maintain a backup file of data. 21 CFR 211.68(b)\nYour systems do not have the appropriate controls to prevent data deletion and record modifications.\nFor example, your firm uses (b)(4) particle counters to perform particle monitoring in classified areas. During the inspection on September 10, 2025, our investigator observed that operators could modify system dates, adjust alarm limits, and access settings without restriction. The equipment displayed that network user authentication was not enforced, and management confirmed that no controls were in place to ensure the integrity of printed data records.\nReview of electronic data stored on your particle counters revealed multiple instances where Grade A action limits for particle counts were exceeded. However, your firm could not produce original printed documentation of these failing results despite extensive searches of batch records and data storage locations. Initial failing particle count results in Grade A areas were not recorded in batch records. Instead, retests were performed, and only conforming retest results were retained and included in production documentation. There was no evidence in batch records of the original failing results or required corrective actions such as notifying operators or cleaning the area.\nAdditionally, you lack adequate data backup and retention procedures. For example, your firm's vendor performed a calibration activity which deleted all electronic data prior to the calibration. You did not have backups of this data.\nYou acknowledged the data integrity failures with your (b)(4) particle counters and proposed several corrective actions. You opened a deviation to document the incident and committed to retraining all personnel on data retention obligations. You purchased new (b)(4) equipment with electronic data collection capabilities that will be connected to a server, proposed to conduct a system-wide review of other in-process control equipment for similar upgrades, and to investigate the root cause of particulate contamination at the (b)(4) machine laminar airflow. You also committed to developing an investment plan for upgrading older equipment and eliminating reliance on paper-based data collection systems.\nYour response is inadequate because it fails to address the immediate and ongoing data integrity risks during the implementation timeline. Your response lacks sufficient interim controls to prevent data manipulation, provides no enhanced Quality Unit oversight of current (b)(4) operations, and offers only \"retraining\" as an immediate remedy for what appears to be data suppression. You did not commit to assessing the impact on already-released batches or implementing enhanced supervision during the interim period.\nIn response to this letter, provide the following:\nA comprehensive, independent assessment of computer system performance and security. Provide a report that identifies vulnerabilities in design and controls, and a thorough corrective action and preventive action (CAPA) plan for each of your laboratory or production computer systems, which contains the following elements:\no A list of all hardware (both standalone and networked) and software used.\no Identification and evaluation of vulnerabilities in performance and security of all of these computer systems, including but not limited to their configurations, administrative rights, password controls, audit trails capabilities and state of implementation for each system, qualification\u002Fvalidation status, deviation history, backup capabilities, network requirements, completeness of data records, suitability of current hardware\u002Fsoftware for its intended use(s), change management, and management oversight.\no An Assessment of each system to determine if unique usernames and passwords are used.\no An evaluation of your policies and procedures regarding computers and data governance with special emphasis on audit trails, prohibiting data deletion, and appropriate modifications of results. Specify how your firm prevents data deletion and undocumented\u002Finappropriate modifications of data. Also describe how you ensure original data and information are always preserved. Provide your procedures for audit trail review. Provide requirements for data retention and backup for all laboratory and production systems.\nA summary of your interim controls to assure reliable performance and security while your CAPA plan is being implemented.\n4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou manufacture prescription (b)(4) dosage form human drug products used to treat various conditions including (b)(4). Your cleaning procedures for your (b)(4), non-dedicated manufacturing equipment was inadequate. For example,\n(b)(4) residues were observed on the gasket of the (b)(4) equipment.\n(b)(4) residues were observed inside the (b)(4) equipment.\nDuring the inspection you collected and analyzed samples of the residue. The active pharmaceutical ingredient (b)(4) was detected.\nIn your response, you state that additional testing had been performed and confirmed the presence of (b)(4), an inactive ingredient which is found in multiple drug products. You then stated that there was no impact on the batches manufactured and distributed, as it was part of the formulation of multiple drug products.\nYour response is inadequate. The presence of (b)(4) from previous batches detected indicates the potential for active ingredients from previous batches to cross contaminate other drug products you manufactured. You failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry. Furthermore, you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from surfaces of your drug product manufacturing equipment.\nIt is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\nIn response to this letter, provide:\nA summary of results from testing retains samples of all drug product batches within expiry manufactured on non-dedicated (b)(4) equipment. You should test all other active ingredients processed in your (b)(4) equipment. Additionally, provide your scientific rationale for any specification related to cross contamination levels. If testing yields an out-of-specification (OOS) result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nAdditional Guidance on Aseptic Processing\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload).4\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nYou must correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of drugs manufactured at Fareva Amboise Zone Industrielle 29, route des industries 37530 Pocé-sur-Cisse - France under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Drugs that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 723502 FEI 3000234005 and ATTN: Dayna I. Martínez when replying.\nSincerely,\n\u002FS\u002F\nDillard Woody\nActing Director\nDivision of Drug Compliance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________\n1 See also, 21 CFR 211.63 (equipment design).\n2 See also, 21 CFR 211.182 (equipment cleaning records).\n3 See also, 21 CFR 211.67 (equipment cleaning and maintenance).\n4 While this document does not specifically reference the Center for Veterinary Medicine, its contents may be helpful as sterile animal drugs and human drugs produced by aseptic processing are subject to the same CGMP requirements.","Fareva Amboise","fareva-amboise-723502-04102026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffareva-amboise-723502-04102026","2026-10-26T08:08:40.035785+00:00","Issued","2026-07-21","723502","Animal & VeterinaryDrugs","Mr. David L. Rapy","2026-08-19T04:28:51.295+00:00","VIA Electronic Mail","2026-04-10",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":20,"letter_url":70,"updated_at":71,"action_type":23,"case_status":49,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":20,"issuing_office":63,"recipient_name":75,"body_fetched_at":76,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":77,"medical_device_id":20,"response_letter_date":20},2728,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022\">AMBI Enterprises LLC \u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Lennarz \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>AMBI Enterprises LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10411 Motor City Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethesda\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20817-1008\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:consumercare@ambi.com\"> consumercare@ambi.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Lennarz:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN\u003Cbr>\n“Fades dark spots for even, natural skin tone . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream NORMAL SKIN\u003Cbr>\n“Fade Cream . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Lennarz\n\nAMBI Enterprises LLC\n\n10411 Motor City Drive\n\nBethesda, MD 20817-1008\n\nUnited States\n\nconsumercare@ambi.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Lennarz:\n\nThis letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\n\nExamples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\n\nAMBI® SKINCARE Fade Cream OILY SKIN\n\n“Fades dark spots for even, natural skin tone . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\n\n“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\n\nAMBI® SKINCARE Fade Cream NORMAL SKIN\n\n“Fade Cream . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\n\n“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________________\n\n1 On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","AMBI Enterprises LLC","ambi-enterprises-llc-628367-04132022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022","2026-10-26T08:07:54.399692+00:00","2022-04-19","628367","Drugs","David Lennarz","2026-08-20T01:59:07.789+00:00","2022-04-13",{"id":79,"raw":80,"subject":86,"body_html":87,"body_text":88,"firm_name":89,"letter_id":90,"created_at":19,"fei_number":20,"letter_url":91,"updated_at":92,"action_type":23,"case_status":49,"posted_date":93,"marcs_cms_no":94,"product_type":95,"closeout_date":20,"issuing_office":96,"recipient_name":97,"body_fetched_at":98,"delivery_method":99,"recipient_title":20,"reference_number":20,"action_taken_date":100,"medical_device_id":20,"response_letter_date":20},1537,[81,82,83,84,85,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-05T05:00:00Z\">12\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023\">Ambaya Gold Health Products, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West IV","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pilar G. Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ambaya Gold Health Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10 Gideon Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sedona\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>86336\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reference: CMS Case # 648130\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Martin:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Brain Balance product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\u003C\u002Fp>\n\n\u003Cp>• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\u003Cbr>\n\u003Cbr>\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\u003Cbr>\n&nbsp; &nbsp; − “1. Powerful anti-inflammatory…”\u003Cbr>\n&nbsp; &nbsp; − “7. Reduce symptoms of depression”\u003Cbr>\n&nbsp; &nbsp; − “8. Lower cholesterol and triglycerides”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\u003Cbr>\n&nbsp; &nbsp; − “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\u003Cbr>\n&nbsp; &nbsp; − “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\u003Cbr>\n&nbsp; &nbsp; − “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\u003Cbr>\n&nbsp; &nbsp; − “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\u003Cbr>\n&nbsp; &nbsp; − “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\u003Cbr>\n&nbsp; &nbsp; − “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\u003Cbr>\n&nbsp; &nbsp; − “[H]elp prevent chronic eye diseases.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Immune System Boost product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\u003Cbr>\n\u003Cbr>\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\u003Cbr>\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\u003Cbr>\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\u003Cbr>\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\u003C\u002Fp>\n\n\u003Cp>On the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\u003Cbr>\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\u003Cbr>\n&nbsp; &nbsp; − “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\u003Cbr>\n&nbsp; &nbsp; − “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\u003Cbr>\n&nbsp; &nbsp; − “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\u003Cbr>\n&nbsp; &nbsp; − “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\u003Cbr>\n&nbsp; &nbsp; − “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Essensiac product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − “[E]ssiac tea…for…reducing inflammation”\u003Cbr>\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\u003C\u002Fp>\n\n\u003Cp>On the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\u003C\u002Fp>\n\n\u003Cp>• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\u003Cbr>\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\u003Cbr>\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\u003Cbr>\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\u003Cbr>\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\u003C\u002Fp>\n\n\u003Cp>• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\u003C\u002Fp>\n\n\u003Cp>• “It assists the body to create an environment that fights against dis-ease…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\u003C\u002Fp>\n\n\u003Cp>• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dentist In A Bottle product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\u003C\u002Fp>\n\n\u003Cp>• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\u003Cbr>\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\u003Cbr>\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\u003C\u002Fp>\n\n\u003Cp>On the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\u003C\u002Fp>\n\n\u003Cp>• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\u003Cbr>\n• “…Effective on Bacteria”\u003Cbr>\n• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\u003Cbr>\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\u003C\u002Fp>\n\n\u003Cp>• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Fulvic Green product\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “2. [R]epair small gut wounds.”\u003Cbr>\n&nbsp; &nbsp; − “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\u003C\u002Fp>\n\n\u003Cp>On the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents &amp; helps with cardiovascular disease”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\u003Cbr>\n&nbsp; &nbsp; − “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\u003Cbr>\n&nbsp; &nbsp; − “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\u003Cbr>\n&nbsp; &nbsp; − “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\u003Cbr>\n&nbsp; &nbsp; − “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\u003Cbr>\n&nbsp; &nbsp; − “Protect Against Liver Disease…Protection against liver disease”\u003Cbr>\n&nbsp; &nbsp; − “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\u003Cbr>\n&nbsp; &nbsp; − “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\u003Cbr>\n&nbsp; &nbsp; − “ANTI-CARCINOGENIC”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\u003Cbr>\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Solution product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − [W]ide-spectrum antibacterial solution minimizes risk of infections”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003C\u002Fp>\n\n\u003Cp>On the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria &amp; viruses...”\u003Cbr>\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\u003C\u002Fp>\n\n\u003Cp>On the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\u003Cbr>\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Detox Cleanse Renew\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\u003Cbr>\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\u003C\u002Fp>\n\n\u003Cp>On the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\u003Cbr>\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\u003Cbr>\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\u003Cbr>\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\u003C\u002Fp>\n\n\u003Cp>“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\u003C\u002Fp>\n\n\u003Cp>“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Magnesium Oil Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\u003C\u002Fp>\n\n\u003Cp>Specifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>Further, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&amp;C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&amp;C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>2, 3&nbsp;&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Your “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>However, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\u003C\u002Fp>\n\n\u003Cp>Thus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>In addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pet Health+ product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\u003C\u002Fp>\n\n\u003Cp>• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\u003Cbr>\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\u003Cbr>\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003Cbr>\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\u003Cbr>\n\u003Cbr>\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\u003C\u002Fp>\n\n\u003Cp>• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\u003C\u002Fp>\n\n\u003Cp>• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\u003C\u002Fp>\n\n\u003Cp>Your Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –\u003Cbr>\nWest Division 4\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&amp;C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPilar G. Martin\n\nRecipient Title\n\nOwner\n\nAmbaya Gold Health Products, LLC\n\n10 Gideon Rd\n\nSedona, AZ 86336\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West IV\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 5, 2023\n\nWARNING LETTER\n\nReference: CMS Case # 648130\n\nDear Ms. Martin:\n\nThis is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nBrain Balance product\n\nOn the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\n\n• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\n\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\n\n• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\n\n− “1. Powerful anti-inflammatory…”\n\n− “7. Reduce symptoms of depression”\n\n− “8. Lower cholesterol and triglycerides”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\n\n• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\n\n− “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\n\n− “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\n\n− “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\n\n− “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\n\n− “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\n\n− “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\n\n− “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\n\n− “[H]elp prevent chronic eye diseases.”\n\nImmune System Boost product\n\nOn the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\n\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\n\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\n\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\n\n• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\n\nOn the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\n\n• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\n\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\n\n− “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\n\n− “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\n\n− “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\n\n− “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\n\n− “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\n\nEssensiac product\n\nOn the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\n\n• On the image of your product label:\n\n− “[E]ssiac tea…for…reducing inflammation”\n\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\n\nOn the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\n\n• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\n\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\n\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\n\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\n\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\n\n• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\n\n• “It assists the body to create an environment that fights against dis-ease…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\n\n• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\n\nDentist In A Bottle product\n\nOn the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\n\n• “Assistance with the prevention of tooth decay”\n\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\n\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\n\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\n\nOn the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\n\n• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\n\n• “…Effective on Bacteria”\n\n• “Assistance with the prevention of tooth decay”\n\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\n\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\n\n• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\n\n• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\n\n• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\n\nFulvic Green product\n\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\n\n− “2. [R]epair small gut wounds.”\n\n− “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\n\nOn the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\n− “[P]revents & helps with cardiovascular disease”\n\n• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\n\n− “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\n\n− “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\n\n− “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\n\n− “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\n\n− “Protect Against Liver Disease…Protection against liver disease”\n\n− “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\n\n− “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\n\n• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\n\n− “ANTI-CARCINOGENIC”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\nSilver Solution product\n\nOn the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\n\n• On the image of your product label:\n\n− [W]ide-spectrum antibacterial solution minimizes risk of infections”\n\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\nOn the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\n\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria & viruses...”\n\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\n\nOn the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\n\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\n\n• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\n\nDetox Cleanse Renew\n\nOn the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\n\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\n\nOn the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\n\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\n\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\n\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\n\nSilver Spray product\n\nOn the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\n\n“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\n\n“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\n\nMagnesium Oil Spray product\n\n“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\n\nSpecifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively1\n\nUnapproved New Drugs\n\nYour Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nFurther, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.2, 3 Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nYour “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).4\n\nHowever, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\n\nThus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nIn addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nUnapproved New Animal Drugs\n\nBased on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\n\nExamples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\n\nPet Health+ product\n\nOn the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\n\n• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\n\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\n\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\n\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\n\n• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\n\n• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\n\n• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\n\nYour Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –\n\nWest Division 4\n\n_____________________\n\n1 It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\n\n2 See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\n\n3 FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).","Ambaya Gold Health Products, LLC","ambaya-gold-health-products-llc-648130-12052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023","2026-10-26T08:07:54.362384+00:00","2024-04-02","648130","Food & Beverages","Division of Human and Animal Food Operations West IV","Pilar G. Martin","2026-08-20T00:12:07.904+00:00","VIA UPS","2023-12-05",{"id":102,"raw":103,"subject":41,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":19,"fei_number":20,"letter_url":111,"updated_at":112,"action_type":23,"case_status":49,"posted_date":113,"marcs_cms_no":114,"product_type":74,"closeout_date":20,"issuing_office":63,"recipient_name":115,"body_fetched_at":116,"delivery_method":117,"recipient_title":20,"reference_number":20,"action_taken_date":118,"medical_device_id":20,"response_letter_date":20},1683,[104,105,106,63,41,13,13,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-13T05:00:00Z\">11\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsudesan-temizlik-urunleri-ve-ambalaj-sanaryi-ticaret-anomin-sirketi-666900-11132023\">Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kemal Deniz\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No:5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>34310\u003C\u002Fspan> \u003Cspan>Avcilar\u003C\u002Fspan>\u002F\u003Cspan>İstanbul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Turkey\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:kdeniz@sudesan.com\"> kdeniz@sudesan.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-05\u003C\u002Fp>\n\n\u003Cp>November 13, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Deniz:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the U.S. Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including Amoray Instant Hand Sanitizer. The FDA has reviewed the records you submitted on March 11, 2022, in response to our August 26, 2021 request for records pursuant to section 704(a)(4) of the Federal, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi (hereafter referred to as Sudesan), FEI 3004647124, at No. 5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak, Avcilar Instanbul.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violation of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR) parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you have not demonstrated that you are adequately testing incoming lots of components used to manufacture your sanitizer drug products.\u003C\u002Fp>\n\n\u003Cp>For example, in response to our 704(a)(4) requests, you provided a list of testing performed on incoming components. Identity testing did not appear to be adequately performed for any of the components. In addition, you failed to adequately describe the physical and microbiological controls that had been implemented. Furthermore, you provided records showing that testing of incoming ethanol lots started after you shipped these drug products to the United States.\u003Cbr>\n\u003Cbr>\nWithout adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA's guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications established to release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not conduct adequate finished drug product testing on all drug products.\u003C\u002Fp>\n\n\u003Cp>Specifically, you failed to provide evidence that you performed identity and strength testing for the active ingredient in your Amoray Hand Sanitizers. In response to our request to provide release test specifications, analytical procedures for the analysis of drug products and testing data, you submitted, in part, a procedure stating you evaluated the alcohol concentration and microbiological attributes of your hand sanitizers. However, the COA reports provided indicate your hand sanitizer drug products were only tested for appearance, odor, density, and pH.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not provide adequate stability data to demonstrate that your program adequately evaluates appropriate storage conditions and supported expiration dates for the drug products manufactured at your facility that are distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>Specifically, the COAs provided by your firm stated the expiration date on your drug products was \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The stability data you provided only covered 12 weeks at controlled room temperature conditions and was limited to drug products manufactured in 2019.\u003C\u002Fp>\n\n\u003Cp>You have not provided data to support the expiry period assigned to your hand sanitizer drug products. Without an adequate stability program, you cannot confirm that your drug products will meet established specifications and all pre-determined quality criteria throughout their shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp;o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should perform a comprehensive audit of your entire operation for CGMP compliance and also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on October 18, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sudesan at No:5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak, Avcilar Istanbul 34310 into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004647124 and ATTN: Marva Taylor.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kemal Deniz\n\nSudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi\n\nNo:5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak\n\n34310 Avcilar\u002Fİstanbul\n\nTurkey\n\nkdeniz@sudesan.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-05\n\nNovember 13, 2023\n\nDear Mr. Deniz:\n\nYour facility is registered with the U.S. Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including Amoray Instant Hand Sanitizer. The FDA has reviewed the records you submitted on March 11, 2022, in response to our August 26, 2021 request for records pursuant to section 704(a)(4) of the Federal, Drug, and Cosmetic Act (FD&C Act) for your facility, Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi (hereafter referred to as Sudesan), FEI 3004647124, at No. 5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak, Avcilar Instanbul.\n\nThis warning letter summarizes significant violation of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR) parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nBased on the records and information you provided, you have not demonstrated that you are adequately testing incoming lots of components used to manufacture your sanitizer drug products.\n\nFor example, in response to our 704(a)(4) requests, you provided a list of testing performed on incoming components. Identity testing did not appear to be adequately performed for any of the components. In addition, you failed to adequately describe the physical and microbiological controls that had been implemented. Furthermore, you provided records showing that testing of incoming ethanol lots started after you shipped these drug products to the United States.\n\nWithout adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA's guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications established to release each incoming lot of components for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nBased on the records and information you provided, you did not conduct adequate finished drug product testing on all drug products.\n\nSpecifically, you failed to provide evidence that you performed identity and strength testing for the active ingredient in your Amoray Hand Sanitizers. In response to our request to provide release test specifications, analytical procedures for the analysis of drug products and testing data, you submitted, in part, a procedure stating you evaluated the alcohol concentration and microbiological attributes of your hand sanitizers. However, the COA reports provided indicate your hand sanitizer drug products were only tested for appearance, odor, density, and pH.\n\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nBased on the records and information you provided, you did not provide adequate stability data to demonstrate that your program adequately evaluates appropriate storage conditions and supported expiration dates for the drug products manufactured at your facility that are distributed to the U.S.\n\nSpecifically, the COAs provided by your firm stated the expiration date on your drug products was (b)(4). The stability data you provided only covered 12 weeks at controlled room temperature conditions and was limited to drug products manufactured in 2019.\n\nYou have not provided data to support the expiry period assigned to your hand sanitizer drug products. Without an adequate stability program, you cannot confirm that your drug products will meet established specifications and all pre-determined quality criteria throughout their shelf life.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should perform a comprehensive audit of your entire operation for CGMP compliance and also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on October 18, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sudesan at No:5 Petrol Ofisi Caddesi Sehit Komando Onbasi Ugur Hanci Sokak, Avcilar Istanbul 34310 into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004647124 and ATTN: Marva Taylor.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi","sudesan-temizlik-urunleri-ve-ambalaj-sanaryi-ticaret-anomin-sirketi-666900-11132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsudesan-temizlik-urunleri-ve-ambalaj-sanaryi-ticaret-anomin-sirketi-666900-11132023","2026-10-26T08:10:06.909195+00:00","2023-12-26","666900","Mr. Kemal Deniz","2026-08-20T00:25:16.261+00:00","Via Email","2023-11-13",5,{"510k":121,"classification":122,"enforcement":123,"event":124,"event_backfill":125,"pma":126,"warning_letter":127},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]